Timely and accurate diagnosis | [11, 13–26] |
More awareness of PF/IPF | [11, 13–15, 18–21, 23, 26, 27] |
Adequate information and education | [11, 13–19, 22–24, 26–32] |
Access to pharmacological treatment | [11, 14, 15, 19–21, 26] |
Interstitial lung disease specialists | [11, 13–16, 18, 19, 22, 25–27] |
Symptom relief | [17, 18, 20, 21, 23, 28, 30] |
Psychological support | [11, 13–15, 17, 23, 26–28] |
More involvement and support of partners | [14, 16, 17, 24, 28, 32, 33] |
Nonpharmacological management (i.e. supplemental oxygen, pulmonary rehabilitation) | [11, 13, 15–17, 19, 21–23, 26, 30] |
Access to a multidisciplinary team | [11, 16, 17] |
End-of-life care | [11, 16, 19, 20, 22, 23, 26–30] |